Replimune Group Q3 EPS Forecast Lowered by Leerink Partnrs

Replimune Group, Inc. (NASDAQ:REPL) – Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Replimune Group in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.71) for the quarter, down from their prior estimate of ($0.64). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.82) EPS and FY2026 earnings at ($2.25) EPS.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07.

Several other research firms have also recently issued reports on REPL. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research note on Tuesday. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $16.80.

Replimune Group Stock Performance

REPL opened at $11.40 on Friday. Replimune Group has a twelve month low of $4.92 and a twelve month high of $12.97. The stock has a market cap of $779.99 million, a PE ratio of -3.74 and a beta of 1.19. The business’s 50 day moving average is $11.44 and its 200-day moving average is $9.50. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares in the last quarter. Braidwell LP boosted its position in Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. Baker BROS. Advisors LP boosted its position in Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after purchasing an additional 699,679 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Replimune Group in the first quarter valued at approximately $1,088,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.